



Shipment to:

Kinderspital Zürich
Zentrum für Pädiatrische Labormedizin (ZPL)
Zentrale Probenannahme
Lenggstrasse 30
CH-8008 Zürich

Contact:

Zentrale Probenannahme: 044 249 66 10
Cytomorphology: 044 249 66 40
Immunphenotyping/FCM-MRD: 044 249 66 50
Oncology Lab MRD: 044 249 68 50
Oncology Lab Cytogenomics: 044 249 68 10

Laboratory Shipment Form for Leukemia

Patient

Name: _____
First name: _____
Date of birth: _____

Sender

Address: _____
Treating physician: _____
Phone: _____
Collection date: _____

Diagnosis (suspected diagnosis)

Therapy protocol:

- ☐ AIEOP-BFM ALL 2017
☐ IntReALL SR 2010 / ALL Relapse
☐ IntReALL HR 2010
☐ EsPhALL2017/COGAALL1631
☐ MyeChild 01
☐ ML-DS 2018
☐ other: _____

Date of initial diagnosis: _____

Under treatment: ☐ yes / ☐ no
Pretreatment: ☐ Transfusions ☐ Neupogen
Therapy timepoint: _____

Diagnostics / Follow-up diagnostics (see following pages, please enclose required pages)

Laboratory values: Please enclose copy of lab report

Leukocytes	_____ G/L	Liquor cell count:	_____ / μ L
Erythrocytes	_____ T/L	Nucleated cells	_____ / μ L
Hemoglobin	_____ g/L	Erythrocytes LQ	_____ / μ L
Thrombocytes	_____ G/L	Macroscop. contaminated with blood?	☐ yes / ☐ no

Material

- | | |
|---|---|
| ☐ Blood smears (6 unstained) | ☐ Liquor (2 cytopsins unstained) |
| ☐ Bone marrow smears (6-8 unstained) | ☐ Heparin-blood |
| Puncture site: _____ | ☐ EDTA-blood |
| ☐ Heparin Bone marrow
(ideally 3x 5ml in tubes without beads and gel, if possible please perform
puncture at 2 sites in the bone through the same puncture site in the skin) | ☐ other: _____ |
| ☐ EDTA-Bone marrow (1x 5 ml for molecular genetic analysis / NGS) | |

Accompanying note AIEOP-BFM ALL 2017 (Interim Phase)

AIEOP-BFM ALL 2017	cyto- morphology	Immunpheno- typing / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
all patients				
☐ initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM	Heparin-BM
☐ day 8	PB smears			
☐ day 15	BM smears	Heparin-BM	Heparin-BM	
☐ day 33 (TP 1)	BM smears		Heparin-BM	
☐ day 78/92 (TP 2)	BM smears*		Heparin-BM	
☐ before protocol II	BM smears*		Heparin-BM	
pB/early HR				
☐ day 64 Consol Bext (TP1a)	BM smears*		Heparin-BM	
pB/MR (National Guidelines for the Interim Phase of AIEOP-BFM-ALL 2017 study)				
☐ start Blina cycle 1 / TP 2	BM smears*		Heparin-BM	
☐ day 29 Blina cycle 1 / start Protocol M	BM smears*		Heparin-BM	
☐ start Blina Cycle 2	BM smears*		Heparin-BM	
☐ day 29 Blina Cycle 2 / start Maintenance	BM smears*		Heparin-BM	
pB/HR (National Guidelines for the Interim Phase of AIEOP-BFM-ALL 2017 study)				
☐ start Blina Cycle 1 / TP 2	BM smears*	Heparin-BM	Heparin-BM	
☐ day 29 Blina Cycle 1 / start HR-1	BM smears*	Heparin-BM	Heparin-BM	
☐ start Blina Cycle 2 / after HR-1	BM smears*		Heparin-BM	
☐ day 29 Blina Cycle 2	BM smears*		Heparin-BM	
☐ after HR-2 (TP HR2) (if applicable)	BM smears*		Heparin-BM	
☐ after HR-3 (if applicable)	BM smears*		Heparin-BM	
☐ before HSCT	BM smears*		Heparin-BM	
☐days /months after HSCT	BM smears*		Heparin-BM	
☐ other timepoint:	*	*	*	*
T/HR (T-ALL)				
☐ day 57 in protokoll IB/2 (TP1b)	BM smears*		Heparin-BM	
☐ after HR-2	BM smears*		Heparin-BM	
☐ after HR-3	BM smears*		Heparin-BM	
☐ before HSCT	BM smears*		Heparin-BM	
☐days / months after HSCT				
☐ other timepoint:	*	*	*	*
CAR-T				
☐ before CAR-T	BM smears*	Heparin-BM	Heparin-BM	
☐days / months after CART	BM smears	Heparin-BM	Heparin-BM	

* Sample will not be analyzed routinely. Asservation only, if nothing else requested

Accompanying note IntReALL SR 2010 (Protocol therapy)

IntReALL SR 2010	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
☐ relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
☐ week 3 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
☐ week 5 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
☐ week 6 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
☐ week 9 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
☐ week 10 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
☐ week 13 (Arm A/B)	BM smears	Heparin-BM	Heparin-BM	
☐ week 15 (Arm B)	BM smears	Heparin-BM	Heparin-BM	
☐ week 16 (Arm A)	BM smears	Heparin-BM	Heparin-BM	
☐ after HSCT	BM smears	Heparin-BM	Heparin-BM	
☐ other timepoint:	*	*	*	*

Accompanying note IntReALL HR 2010

IntReALL HR 2010	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
☐ relapse diagnosis	BM smears PB smears CSF cytospins	Heparin-BM	Heparin-BM	Heparin-BM
☐ week 5 (before HC1)	BM smears	Heparin-BM	Heparin-BM	
☐ week 8 (before HC2)	BM smears	Heparin-BM	Heparin-BM	
☐ week 11 (before HC3)	BM smears	Heparin-BM	Heparin-BM	
☐ before HSCT	BM smears	Heparin-BM	Heparin-BM	
☐ other timepoint:	*	*	*	*

Accompanying note EsPhALL2017/COGAALL1631 (Interim Phase)

EsPhALL2017/COGAALL1631	Cyto- morphology	Immuno- phenotyping / FCM-MRD	Molecular- genetics / PCR-MRD	Cytogenomics
☐ initial	BM smears PB smears CSF cytopins	Heparin-BM	Heparin-BM	Heparin-BM
☐ after protocol IB	BM smears	Heparin-BM	Heparin-BM	
SR (National Guidelines)				
☐ day 29 Blina Cycle 1	BM smears		Heparin-BM	
☐ after HD-MTX Interim Maintenance	BM smears		Heparin-BM	
☐ day 29 Blina Cycle 2	BM smears		Heparin-BM	
☐ after Capizzi-MTX Interim Maintenance	BM smears		Heparin-BM	
HR (National Guidelines)				
☐ day 29 Blina Cycle 1	BM smears		Heparin-BM	
☐ after Consolidation #1	BM smears		Heparin-BM	
☐ day 29 Blina Cycle 2	BM smears		Heparin-BM	
☐ before HSCT	BM smears		Heparin-BM	
☐ other timepoint:	*	*	*	*

Accompanying note MyeChild 01 (Protocol therapy)

MyeChild 01	Cyto-morphology	Immuno-phenotyping / FCM-MRD	Molecular-genetics / PCR-MRD	Cytogenomics
☐ initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM Heparin-PB	Heparin-BM
Course 1				
☐ post course 1	BM smears	Heparin-BM	Heparin-BM Heparin-PB	
Course 2				
☐ post course 2	BM smears	Heparin-BM	Heparin-BM Heparin-PB	
Course 3				
☐ post course 3	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
☐ before HSCT (if applicable)	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
☐ end of therapy	BM smears*	Heparin-BM	Heparin-BM Heparin-PB	
HSCT (if applicable)				
☐ 1 month after HSCT (if applicable)		Heparin-BM	Heparin-BM	
☐ day 100 after HSCT (if applicable)		Heparin-BM	Heparin-BM	
☐ 6 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
☐ 9 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
☐ 12 months after HSCT (if applicable)		Heparin-BM	Heparin-BM	
☐ other timepoint:	*	*	*	*

* sample will not be analyzed routinely. storage only, if nothing else requested

Accompanying note ML-DS 2018 (Protocol therapy)

ML-DS 2018	Cyto-morphology	Immuno-phenotyping / FCM-MRD	Molecular-genetics / PCR-MRD	Cytogenomics
☐ initial	BM smears PB smears CSF cytopspins	Heparin-BM	Heparin-BM	Heparin-BM
☐ day 28 *	BM smears	Heparin-BM *	Heparin-BM *	
☐ day 56	BM smears		Heparin-BM	
☐ day 84	BM smears		Heparin-BM	
☐ day 112	BM smears		Heparin-BM	
☐ other timepoint:	*	*	*	*

* **ML-DS 2018 study patients:** additional shipment on day 28 by the local clinic to the ML-DS reference laboratory Frankfurt (acc.to CH-appendix):
-1-5 ml bone marrow (Heparin or EDTA) for Immunphenotyping
-4 ml bone marrow (EDTA) for Moleculargenetics